KNSA vs NVS: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

NVS is the larger of the two ($286.41B market cap): the incumbent the market prices for continued execution (15.27x forward earnings, beta 0.45). KNSA is the smaller challenger ($7.39B), actually pricier on forward earnings (46.00x): more room to run, but more to prove. If you believe in growth, KNSA fits: analysts expect its revenue to rise 28% next year, against 7% for NVS. If you believe in paying less for profit, NVS fits: it trades at 15.27x forward earnings, against 46x for KNSA.

KNSA vs NVS: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricKNSANVSWhat it tells you
Market cap$7.39B$286.41BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E46.0015.27Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E71.2728.94Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.080.45Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range92% of range58% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book10.407.69How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: NVS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how KNSA and NVS affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. KNSA and NVS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined KNSA and NVS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Kiniksa Pharmaceuticals (KNSA) do?

Kiniksa Pharmaceuticals (Nasdaq: KNSA) is a commercial-stage biopharmaceutical company focused on immune-modulating and cardiovascular therapies. Its franchise is ARCALYST (rilonacept), an IL-1 blocker approved for recurrent pericarditis (a painful inflammatory condition of the heart lining) that it commercializes in the US under a collaboration with Regeneron. ARCALYST drove roughly $677.5 million of net product revenue in 2025, up about 62% from 2024. Growth kept accelerating in 2026: revenue was roughly $214.3 million in Q1 (up about 56% year over year), $243.6 million in Q2 (up about 55%) and about $286 million in Q3 (up about 58%), and management has raised full-year 2026 net product revenue guidance three times, most recently to $1.045 to $1.050 billion. About 5,450 clinicians had prescribed ARCALYST by the end of Q3, roughly 450 more than a quarter earlier, and management estimates it has reached about 23% of the roughly 14,000-patient multiple-recurrence population.

Full KNSA guide

What does Novartis AG (NVS) do?

Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. Over the past several years it deliberately reshaped itself into a pure-play innovative-medicines business: it spun off the Alcon eye-care division in 2019 and separated the Sandoz generics and biosimilars unit in 2023, distributing those shares to Novartis holders. What remains is a focused portfolio of patented prescription drugs concentrated in four therapeutic areas: oncology, immunology, neuroscience, and cardiovascular-renal-metabolic disease. Oncology is its largest contributor, and the company has built a reputation for high core operating margins, reaching roughly 40% in 2025. Revenue was about $56.7 billion in 2025, roughly 10% above 2024, and trailing twelve-month revenue is about $57.4 billion with net income near $10.0 billion.

Full NVS guide

KNSA vs NVS: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • KNSA drivers: ARCALYST adoption in recurrent pericarditis; Profitable growth profile.
  • NVS drivers: Priority growth brands offsetting the cliff; Focused, high-margin innovative-medicines model.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is single-product concentration: essentially all revenue depends on ARCALYST in one indication, so any competitive entry, reimbursement pressure, safety signal, or eventual loss of exclusivity would be material. For NVS, the dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed.

KNSA or NVS: which should you pick?

If the story you believe is KNSA's (ARCALYST adoption in recurrent pericarditis), KNSA is the more direct way to own it; if it is NVS's (Priority growth brands offsetting the cliff), NVS is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the KNSA and NVS guides.

KNSA vs NVS: the full fundamentals

KNSA. As of November 2026, Kiniksa carried a market cap of roughly $7.4 billion against trailing revenue near $946 million and net income around $110 million, for a trailing P/E near 71. That multiple reflects both rare biotech profitability and expectations that ARCALYST keeps compounding past the raised 2026 guidance and that analysts' forecast of about $1.35 billion of 2027 revenue and $2.05 of EPS holds. The seven analysts in Yahoo's count rate it a strong buy with a mean target near $112, and the stock is up about 124% in 2026.

NVS. At about $152, NVS trades near 29 times trailing earnings but only about 15 times forward estimates, a gap that widened after a third quarter in which reported profit fell to about $1.2 billion while core EPS beat. Analysts expect EPS of about $9.07 in 2026 and $9.93 in 2027. The analyst mean target of roughly $157 sits close to the current price, so how fast the growth brands keep absorbing the generic erosion, and the run of pipeline readouts into 2027, matter more than any single trailing figure. Figures are approximate and tied to the asOf date; verify live numbers before acting.

Headline figures (approximate, November 2026): KNSA shows revenue (ttm) ~$946M, q3 2026 revenue ~$286M (up ~58% YoY), net income (ttm) ~$110M (EPS ~$1.32), margins (ttm) ~54% gross, ~14% operating, ~12% net; NVS shows revenue (ttm) ~$57.4B; Q3 2026 revenue ~$15.03B, up ~5% year over year, growth drivers Priority brands Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix offsetting Entresto's generic decline, margins (ttm) ~75% gross, ~34% operating, ~17.5% net, net income (ttm) ~$10.0B.

The bottom line: KNSA vs NVS

KNSA and NVS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined KNSA and NVS exposure against your real portfolio. It is not an investment adviser.

Wondering how KNSA or NVS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Kiniksa Pharmaceuticals

Ask Walnut's AI anything about KNSA and see how it fits what you own.

FAQ

What is the difference between KNSA and NVS?

+

Kiniksa Pharmaceuticals (Nasdaq: KNSA) is a commercial-stage biopharmaceutical company focused on immune-modulating and cardiovascular therapies. Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is KNSA or NVS the better stock?

+

Neither is universally better. NVS is the larger incumbent; KNSA is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, KNSA or NVS?

+

On forward P/E (as of November 2026), KNSA trades at 46.00x and NVS at 15.27x, so NVS is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both KNSA and NVS?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of KNSA vs NVS?

+

KNSA: The dominant risk is single-product concentration: essentially all revenue depends on ARCALYST in one indication, so any competitive entry, reimbursement pressure, safety signal, or eventual loss of exclusivity would be material. The stock trades at about 71 times trailing and 46 times forward earnings after more than doubling over the past year, so a growth deceleration or a guidance miss could compress the valuation sharply; quarterly EPS missed estimates in late 2025 even as revenue grew. Insiders sold several blocks of shares in November 2026 after the rally. The pipeline remains binary: a PASTORALE failure, with data expected in the second half of 2027, would remove the main franchise-extension thesis, and KPL-1161 has not yet entered the clinic. ARCALYST is co-developed with Regeneron, so collaboration economics and terms matter to Kiniksa's share of profits. As a small-cap biotech, the shares are volatile and sensitive to single data readouts. NVS: The dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed. Analysts expect 2026 EPS to be about flat before rising about 10% in 2027, and reported earnings fell about 69% year over year in the latest quarter. Pipeline risk is structural because late-stage trials can fail and regulators can reject or delay approvals, turning expected future revenue into a write-off, as pelacarsen's failed HORIZON outcomes trial did in 2026. Large acquisitions such as Avidity add integration and financing risk and raised debt, which stood at about $48 billion against about $8.9 billion of cash at September 30, 2026. US drug-pricing policy, potential pharmaceutical tariffs, and pricing pressure are outside the company's control and could compress margins, and in November 2026 the CEO warned that US limits on investment in Chinese biotech could hurt drug development. Because NVS is a Swiss ADR, US investors also carry dollar-versus-Swiss-franc currency risk, and Swiss dividend withholding tax reduces net income for some holders. Concentration in a handful of growth drugs means a single clinical or commercial setback can move the stock.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell KNSA or NVS; figures are approximate and dated (as of November 2026). Verify current data before investing.